Please stand by. We are about to begin. Good day, and welcome to the Eyenovia third quarter 2022 earnings call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Eric Ribner, LifeSci Advisors. Please go ahead. Thanks, everyone, and good afternoon. Welcome to Eyenovia's third quarter 2022 earnings conference call and audio webcast. With me today are Eyenovia's Chief Executive Officer, Michael Rowe, and Chief Financial Officer, John Gandolfo. This afternoon, Eyenovia issued a press release announcing financial results for the three months ended September 30, 2022. We encourage everyone to read today's press release, as well as Eyenovia's annual report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 30, 2022, and our most recently filed 10-Q. The company's press release and annual report are also available on Eyenovia's website at www.eyenovia.com. In addition, this conference call is being webcast through the company's website and will be archived for future reference. Please note that on today's call we will be discussing investigational product candidates which have yet to receive FDA approval. Please also note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Eyenovia's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are subject to a number of risks which are described in more detail in our annual report on Form 10-K and our most recently filed 10-Q. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 10, 2022. Eyenovia undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law. With that said, I'd like to turn the call over to Michael Rowe, Eyenovia's Chief Executive Officer. Michael? Thank you, Eric, and welcome everyone to our third quarter 2022 financial results conference call. It's been about 100 days since I've taken over the CEO role from Dr. Ianchulev, and we have been laser focused on increasing our company's value by advancing our key programs. I will provide an operational update and then turn the call over to John Gandolfo, our CFO, for a review of the financials. I would like to begin with MydCombi, which is our proprietary combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation. In October of last year, we received a complete response letter, or CRL, from the FDA indicating that MydCombi had been reclassified as a drug device combination product, which ultimately necessitated additional testing of the Optejet dispensing device. The additional tests included a microbial challenge study that demonstrated the ability of the Optejet to keep microbes from entering the device, a human factor study assessing the ability of users to follow cleaning instructions for the device, an electronic safety study, and a study on aged devices to ensure their long-term reliability. All of these tests have now been successfully completed. It is important to note here that these additional tests were non-clinical in nature. No additional clinical data was requested. The original NDA was supported by two successful phase 3 clinical trials, MIST-1 and MIST-2. With the additional device testing complete, we recently resubmitted our NDA and our MydCombi NDA. Per normal procedures, the FDA has 30 days from that submission to review our NDA for completeness and to notify us of its acceptance. Once our NDA is accepted, we would anticipate a six-month review process from the date of the resubmission, which could result in approval around mid-year 2023 if all goes as anticipated. If approved, MydCombi would represent an important validation of the Optejet technology, which has been shown in previous studies to deliver a therapeutic dose of medication with significantly less drug and preservative exposure as compared to standard eye drops. This validation is important not only for our other proprietary programs and our existing partnerships with Bausch + Lomb and Arctic Vision, but also for future potential partnerships where the benefits of the Optejet may be leveraged in other high-value ophthalmic indications. It is also worth noting that the additional device validation testing that we conducted for the MydCombi NDA may be referenceable in filings for our presbyopia and progressive myopia programs, potentially streamlining those regulatory review processes in the future. MydCombi potentially represents our first commercial product, and so we regard the successful resubmission of our NDA as a significant achievement for our company. Let's move on to MicroLine, which is our proprietary topical on-demand pilocarpine-based therapeutic candidate that we are developing for the temporary improvement in near vision associated with presbyopia. Presbyopia is the age-related hardening of the eye's lens, causing blurred near vision. This is an addressable market representing over 18 million people in the United States alone between the ages of 40 and 55 who otherwise never wore glasses and have the resources for a cash pay product. In terms of dollars, our proprietary market research suggests that this could be a multi-billion dollar annual market in the US alone. Just a few weeks ago, we announced positive results from VISION-2, which is our second phase 3 study of MicroLine. In a modified per protocol analysis of evaluable patients, excluding a non-study related adverse event impacting pupil size or reactivity, otherwise known as new onset anisocoria, VISION-2 met its primary endpoint with a statistically significant proportion of subjects treated with MicroLine showing a 15 letter or more improvement in distance corrected near visual acuity with less than a 5 letter loss in distance acuity versus placebo in low light conditions at 2 hours post-treatment. The study also achieved all secondary endpoints with statistical significance. Of particular note is the compelling safety and tolerability profile of the product. Consistent with prior studies, MicroLine was found to be very well tolerated, with fewer than 3% of MicroLine treated subjects reporting adverse events, all of which were considered mild and transient. This compares very favorably to other pilo-based presbyopia treatments, where about 15% of study subjects reported some form of headache or brow ache. Vision 2 follows the successful outcome of the VISION- 1 study that we announced in May of last year. The VISION -1 study evaluated the safety and efficacy of our 1% and 2% pilocarpine Micro-Array Print formulations versus placebo, all administered via the Optejet. With VISION -1 and 2, we now have completed 4 studies demonstrating the utility of Optejet's microdose array print technology in improving the therapeutic index of topical ophthalmic drugs. In terms of next steps, we plan to request a meeting with the FDA to hopefully be held in early 2023 to review the totality of data compiled on MicroLine to date and to gain alignment on remaining regulatory steps. Following that meeting, we plan to initiate the manufacture of registration batches at our new state-of-the-art facility in Redwood City, California. We believe there is a significant market opportunity for our spray presbyopia treatment, an alternative to reading glasses when wearing glasses is undesirable. We believe the Optejet will allow us to capture a significant share of this market, irrespective of the number of eye drop products that may be on the market when we hopefully launch. Now, for the benefit of those of you who may be new to our story, Optejet is our proprietary dispensing device which we incorporate across all of our development programs. It offers significant advantages as compared to standard eye drops, which are difficult to use and can overdose the eye by as much as 300%. This overdosing has been shown to cause potentially dangerous ocular and systemic side effects over time. Speaking of ocular side effects, recent studies of a human conjunctival cell line conducted with Tufts University demonstrated that the Optejet can minimize the impact of preserved medications on the ocular surface. In fact, preserved medication delivered to the Optejet acted very similar to non-preserved eye drops with respect to cell viability, cytotoxicity, apoptosis and metabolic activity in the study. The Optejet is also significantly easier to use than conventional drops. Since it delivers medication horizontally, there is no need to tilt one's head back and there is no drug overflow. This helps increase compliance, especially among children. There is the form factor. It is simply a sophisticated looking device. Finally, the Optejet is equipped with smart technology that can be paired with devices for the purpose of remote therapeutic monitoring. Earlier this year, we surveyed 100 glaucoma treating ophthalmologists and optometrists to gauge their interest in remote therapeutic monitoring of patients of a type that Optejet's smart technology can provide. Of the providers surveyed, 98% said that the understanding of compliance and adherence behavior with glaucoma medications was important, with 93% saying it was very important. Notably, almost all providers thought that the availability of the new CPT code for remote therapeutic monitoring or RTM would lead to better patient outcomes. Delivering the right dose, making administration easier, minimizing side effects, and improving communication between doctor and patient are just some of the reasons that we feel the Optejet is a paradigm shift in topical ophthalmic medication delivery. We look forward to bringing this technology to not just our own development programs, but through partnering to bring these benefits into the program of others. Before turning the call over to John to review the financials, I want to acknowledge the recent retirement of Ken Lee from our board of directors. Ken has been a valued member of both our board of directors and the Eyenovia family since 2018, and has made many key contributions to our strategy over the years, particularly as it pertains to the resubmission of our MydCombi NDA. We wish him well in his retirement, and we are encouraged that he has agreed to remain available to us for advice and consultation in the future. I would now like to turn the call over to our Chief Financial Officer, John Gandolfo, to provide a financial update. John? Thank you, Michael. For the third quarter of 2022, we reported a net loss of approximately $7.3 million, or $0.21 per share on approximately 34.6 million weighted average shares outstanding. This compares to a net loss of approximately $5.6 million, or $0.21 per share for the third quarter of 2021 on approximately 26 million weighted average shares outstanding. Research and development expenses totaled approximately $3.9 million for the third quarter of 2022. This compares to approximately $3.6 million for the same period in 2021, an increase of 9.1%. For the third quarter of 2022, general and administrative expenses were approximately $3.4 million compared with approximately $2.4 million for the third quarter of 2021, an increase of approximately 41.3%. Total operating expenses for the third quarter of 2022 were approximately $7.2 million compared to total operating expenses of $5.9 million for the same period in 2021. This represents an increase of approximately 22%. As of September 30, 2022, the company's unrestricted and restricted cash balance was approximately $25.3 million, including $7.9 million of restricted cash. In early November, we paid off our outstanding Silicon Valley Bank loan with our restricted cash funds and which was collateralizing the loan. Over the near term, we are focusing our efforts on raising capital through a non-dilutive financing transaction as well as closing on an additional technology licensing transaction. Before we open the call to questions, I will conclude with a brief update on our licensing programs with Bausch + Lomb for MicroPine in the US and Canada, and Arctic Vision for all three of our products in China and South Korea. MicroPine is a proprietary atropine formulation for the reduction of pediatric myopia progression. It has been shown in clinical studies to slow myopia progression by 60% or more. There are currently no FDA-approved drug therapies for this indication, and if left untreated, this can result in retinal detachment, myopic retinopathy, and vision loss. Bifocal, multifocal glasses or contact lenses are typically prescribed to myopic children. Recall that as part of the agreement with Bausch + Lomb, oversight and costs related to the ongoing phase 3 CHAPERONE MicroPine clinical trial were transferred to our partner. CHAPERONE is a 48-month US-based multicenter randomized double-masked trial that is enrolling more than 400 children between 3 and 12 years of age. The trial is comparing micro-dosed atropine 0.01% versus placebo ophthalmic solution. Enrollment is progressing as planned. Our agreement with Arctic Vision covers Greater China and South Korea. While the original agreement that we announced in August 2020 was for MicroPine and MicroLine, Arctic Vision also subsequently added MydCombi as well. Arctic Vision is now licensing all three of our current programs. MicroPine for pediatric myopia, in particular, represents a significant opportunity in China. The Ministry of Education estimates that nearly 53% of all Chinese children suffered from myopia in 2020, and 13 million children are estimated to be at the highest risk. Our agreement with Arctic Vision provides for sales royalties in addition to development milestones. If and when approved, MicroPine could be a significant source of non-dilutive funds for our company over the long term. Finally, we recently announced that Arctic Vision has now enrolled the first patient in its presbyopia study. This marks the first time that a clinical trial has been approved in China to evaluate a pharmacologic treatment for presbyopia, so that program is progressing very nicely. To date, our license agreement have generated approximately $16 million in license fees, and we have the potential to earn an additional $60 million in net license and development milestones, as well as reimbursable expenses over the next four years. As noted upon commercialization, if approved, Eyenovia can earn significant sales royalties from its products as well. We are also continuing to assess potential pipeline expansion opportunities as we believe we can leverage the Optejet technology to address unmet needs in additional large ophthalmic indications. Some examples include anti-infectives, anti-inflammatories, dry eye, and glaucoma, each with significant market opportunities. Pipeline expansion was a significant consideration as we were building out our new Redwood City facility. In conclusion, we continue to be pleased with our performance to date. To summarize our key highlights, we achieved two key milestones, the resubmission of our NDA for MydCombi and the positive completion of our VISION-2 presbyopia study for MicroLine. We executed on the planned CEO transition and added significant expertise to our board of directors. Our new state-of-the-art manufacturing facility in Redwood City, California, is now operational and provides significant additional capacity to complement our existing contract manufacturing relationships. Our license agreements with Arctic Vision and Bausch + Lomb are progressing well and continue to offer the opportunity for meeting development and regulatory milestones, as well as line of sight to potential sales royalties possibly within the next two years. That concludes our prepared remarks. We would now like to open the call to questions. Operator? Of course. Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. If you're using a speakerphone, please make sure mute function is turned off to allow your signal to reach our equipment. Again, it is star one if you would like to ask a question. We'll pause just for a moment to allow everyone an opportunity to signal for questions. Again, it is star one if you would like to ask a question. We'll take our first question from Len Yaffe with Stock Davis OC. Please go ahead. Oh, hi. Thanks so very much. I had a couple questions for you, and I apologize. I was late to the call, so if you went over this, please feel free to pass. I was at the optometry meeting down in San Diego a couple weeks ago, and one of the things I noticed as I spoke to a lot of the optometrists down there is that there seems to be a lot of interest in the device for its application for making their life easier, either with fussy patients or younger patients. I'm talking about, you know, with MydCombi. I was just wondering if you could shed any light on that. The second thing is VUITY is not off to a really good start, and some of that might be the way they thought the market would develop with chronic use rather than PRN use. Could you discuss your data in terms of the improvements you're getting in visual acuity, near vision versus what other companies have had? On the other side, as it relates to brow ache, headache, your data versus others. Thanks so very much. Thank you, Len, and thanks for the questions and calling in. In response to your first one with the optometrists and the use of the Optejet device, yeah, we have seen that there's a lot of interest, especially among doctors who treat younger patients and kids, that they're telling us to put dilation drops or basically any dry eye drops into children is an ordeal. When they see the Optejet and we have it down there, the demo for them, they immediately saw they had great interest in using that specifically for those patients right off the bat. Which was interesting because it wasn't exactly something that we had paid a lot of attention to before. Now because we're seeing that kind of interest and acceptance, we're adding that to our targets when we do eventually commercialize MydCombi, hopefully the middle of next year. That was a learning on all of us. A very pleasant learning for all of us. For your second question on the efficacy, our efficacy related to VUITY and the VUITY launch, I'm not gonna go into you know, how the VUITY launch was done and how Allergan now is coming back and basically doing a relaunch the way probably it should have been done. What I will say is that they're pilocarpine, we are pilocarpine. The actual efficacy in improving patients getting 15 letters is very, very similar between the two drugs. If you compare at the same time point in the study, at the same days in the study, they're very similar. What's not similar is the side effect profile, where our product has fewer than 3% of patients have any kind of, adverse event, and the adverse events are mild and transient. Of that, even less than that is brow ache or headache. We know from our own market research that, once you get over 5% brow ache or headache, it really, really dampens people's interest in using the product. That's a key part of what we offer. I think where we benefit is that people really like the Optejet device. They like not having to put in eye drops. They like the spray a lot more. The efficacy will be very similar, but the side effect profile will be better. Our value proposition is to provide patients with functional vision so that they're able to do things like see their telephone, so they're able to read a menu, they can fill in a scorecard playing golf. That's what this is really intended for. Not really have to worry that they're going to get some kind of adverse event that's gonna, you know, give them a headache. Thanks for the question. Thank you. As another reminder, it is star one if you would like to ask a question. It appears we have no further questions. All right. Well, that makes it easier. That concludes today's call. We hope we were successful in conveying the significant progress that we continue to make with the Optejet technology and across our key clinical programs. We have 1 NDA now pending with the FDA and a second late-stage program that we will be discussing with the FDA early next year. Quite simply, we believe we have potential line of sight to 2 commercial products. There are also a number of emerging opportunities to license out Optejet technology for additional high-value ophthalmic indications. We believe we have reached an inflection point in Eyenovia's evolution and look forward to positive and potentially value-creating developments in the next year. Again, thank you all for joining us, and have a good evening. With that does conclude today's call. Thank you for your participation. You may now disconnect.